Solitary Tumefactive Demyelinating Lesions in Children: Clinical and Magnetic Resonance Imaging Features, Pathologic Characteristics, and Outcomes

IF 3.2 3区 医学 Q2 CLINICAL NEUROLOGY
Sarah Frankl MD , Angela Viaene MD, PhD , Arastoo Vossough MD, PhD , Amy Waldman MD , Sarah Hopkins MD, MSPH , Brenda Banwell MD
{"title":"Solitary Tumefactive Demyelinating Lesions in Children: Clinical and Magnetic Resonance Imaging Features, Pathologic Characteristics, and Outcomes","authors":"Sarah Frankl MD ,&nbsp;Angela Viaene MD, PhD ,&nbsp;Arastoo Vossough MD, PhD ,&nbsp;Amy Waldman MD ,&nbsp;Sarah Hopkins MD, MSPH ,&nbsp;Brenda Banwell MD","doi":"10.1016/j.pediatrneurol.2024.05.012","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Isolated tumefactive demyelinating lesions (≥2 cm) may be difficult to distinguish from contrast-enhancing brain tumors, central nervous system infections, and (rarely) tissue dysgenesis, which may all occur with increased signal on T2-weighted images. Establishing an accurate diagnosis is essential for management, and we delineate our single-center experience.</p></div><div><h3>Methods</h3><p>We performed a retrospective review of medical records, imaging, and biopsy specimens for patients under 18 years presenting with isolated tumefactive demyelination over a 10-year period.</p></div><div><h3>Results</h3><p>Ten children (eight female) met inclusion criteria, with a median age of 14.1 years. Lesions were most likely to involve the thalamus (six of 10), brainstem (five of 10), basal ganglia (four of 10), or corpus callosum (four of 10). Eighty percent had perilesional edema at presentation, and 60% had midline shift. Biopsies demonstrated demyelination with perivascular lymphocytic infiltration and axonal damage ranging from mild to severe. All patients were initially treated with high-dose corticosteroids, and eight of 10 required additional medical therapies such as intravenous immunoglobulin, plasmapheresis, cyclophosphamide, or rituximab. Increased intracranial pressure was managed aggressively with two of 10 patients requiring decompressive craniectomies. Clinical outcomes varied.</p></div><div><h3>Conclusions</h3><p>Solitary tumefactive demyelinating lesions are rare, and aggressive management of inflammation and increased intracranial pressure is essential. Biopsy is helpful to evaluate for other diagnoses on the differential and maximize therapies. Treatment beyond initial therapy with corticosteroids is often required. Isolated tumefactive demyelinating lesions are uncommon; multicenter natural history studies are needed to better delineate differential diagnoses and optimal therapies.</p></div>","PeriodicalId":19956,"journal":{"name":"Pediatric neurology","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric neurology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0887899424002030","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Isolated tumefactive demyelinating lesions (≥2 cm) may be difficult to distinguish from contrast-enhancing brain tumors, central nervous system infections, and (rarely) tissue dysgenesis, which may all occur with increased signal on T2-weighted images. Establishing an accurate diagnosis is essential for management, and we delineate our single-center experience.

Methods

We performed a retrospective review of medical records, imaging, and biopsy specimens for patients under 18 years presenting with isolated tumefactive demyelination over a 10-year period.

Results

Ten children (eight female) met inclusion criteria, with a median age of 14.1 years. Lesions were most likely to involve the thalamus (six of 10), brainstem (five of 10), basal ganglia (four of 10), or corpus callosum (four of 10). Eighty percent had perilesional edema at presentation, and 60% had midline shift. Biopsies demonstrated demyelination with perivascular lymphocytic infiltration and axonal damage ranging from mild to severe. All patients were initially treated with high-dose corticosteroids, and eight of 10 required additional medical therapies such as intravenous immunoglobulin, plasmapheresis, cyclophosphamide, or rituximab. Increased intracranial pressure was managed aggressively with two of 10 patients requiring decompressive craniectomies. Clinical outcomes varied.

Conclusions

Solitary tumefactive demyelinating lesions are rare, and aggressive management of inflammation and increased intracranial pressure is essential. Biopsy is helpful to evaluate for other diagnoses on the differential and maximize therapies. Treatment beyond initial therapy with corticosteroids is often required. Isolated tumefactive demyelinating lesions are uncommon; multicenter natural history studies are needed to better delineate differential diagnoses and optimal therapies.

儿童孤立性肿瘤性脱髓鞘病变:临床和磁共振成像特征、病理特征和结果
背景孤立的肿瘤活性脱髓鞘病变(≥2 厘米)可能很难与对比度增强型脑肿瘤、中枢神经系统感染和(罕见的)组织发育不良相鉴别,这些病变在 T2 加权图像上都可能出现信号增高。方法我们对10年间18岁以下孤立性肿瘤活性脱髓鞘患者的病历、影像学检查和活检标本进行了回顾性分析。结果10名儿童(8名女性)符合纳入标准,中位年龄为14.1岁。病变最有可能累及丘脑(10 例中有 6 例)、脑干(10 例中有 5 例)、基底节(10 例中有 4 例)或胼胝体(10 例中有 4 例)。80%的患者在发病时有周围水肿,60%有中线移位。活组织检查显示脱髓鞘,血管周围有淋巴细胞浸润,轴索损伤程度从轻微到严重不等。所有患者最初都接受了大剂量皮质类固醇治疗,10人中有8人需要额外的药物治疗,如静脉注射免疫球蛋白、血浆置换术、环磷酰胺或利妥昔单抗。对颅内压增高的患者采取了积极的治疗措施,10 例患者中有 2 例需要进行减压开颅手术。结论孤立性肿瘤性脱髓鞘病变非常罕见,必须积极治疗炎症和颅内压增高。活组织检查有助于评估鉴别诊断中的其他诊断,并最大限度地提高治疗效果。除了使用皮质类固醇进行初始治疗外,通常还需要进行其他治疗。孤立的肿瘤活动性脱髓鞘病变并不常见;需要进行多中心自然病史研究,以更好地确定鉴别诊断和最佳疗法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pediatric neurology
Pediatric neurology 医学-临床神经学
CiteScore
4.80
自引率
2.60%
发文量
176
审稿时长
78 days
期刊介绍: Pediatric Neurology publishes timely peer-reviewed clinical and research articles covering all aspects of the developing nervous system. Pediatric Neurology features up-to-the-minute publication of the latest advances in the diagnosis, management, and treatment of pediatric neurologic disorders. The journal''s editor, E. Steve Roach, in conjunction with the team of Associate Editors, heads an internationally recognized editorial board, ensuring the most authoritative and extensive coverage of the field. Among the topics covered are: epilepsy, mitochondrial diseases, congenital malformations, chromosomopathies, peripheral neuropathies, perinatal and childhood stroke, cerebral palsy, as well as other diseases affecting the developing nervous system.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信